IBDEI1AX ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,23055,1,5,0)
 ;;=5^Hx of CHF
 ;;^UTILITY(U,$J,358.3,23055,2)
 ;;=^303399
 ;;^UTILITY(U,$J,358.3,23056,0)
 ;;=V45.81^^125^1400^29
 ;;^UTILITY(U,$J,358.3,23056,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23056,1,4,0)
 ;;=4^V45.81
 ;;^UTILITY(U,$J,358.3,23056,1,5,0)
 ;;=5^Hx of CABG
 ;;^UTILITY(U,$J,358.3,23056,2)
 ;;=^97129
 ;;^UTILITY(U,$J,358.3,23057,0)
 ;;=V15.84^^125^1400^28
 ;;^UTILITY(U,$J,358.3,23057,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23057,1,4,0)
 ;;=4^V15.84
 ;;^UTILITY(U,$J,358.3,23057,1,5,0)
 ;;=5^Hx of Asbestos Exposure
 ;;^UTILITY(U,$J,358.3,23057,2)
 ;;=^303406
 ;;^UTILITY(U,$J,358.3,23058,0)
 ;;=V15.85^^125^1400^47
 ;;^UTILITY(U,$J,358.3,23058,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23058,1,4,0)
 ;;=4^V15.85
 ;;^UTILITY(U,$J,358.3,23058,1,5,0)
 ;;=5^Hx of Potentially Hazardous Body Fluids
 ;;^UTILITY(U,$J,358.3,23058,2)
 ;;=^303407
 ;;^UTILITY(U,$J,358.3,23059,0)
 ;;=V10.72^^125^1400^34
 ;;^UTILITY(U,$J,358.3,23059,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23059,1,4,0)
 ;;=4^V10.72
 ;;^UTILITY(U,$J,358.3,23059,1,5,0)
 ;;=5^Hx of Hodgkin's Disease
 ;;^UTILITY(U,$J,358.3,23059,2)
 ;;=^295237
 ;;^UTILITY(U,$J,358.3,23060,0)
 ;;=V15.3^^125^1400^35
 ;;^UTILITY(U,$J,358.3,23060,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23060,1,4,0)
 ;;=4^V15.3
 ;;^UTILITY(U,$J,358.3,23060,1,5,0)
 ;;=5^Hx of Irradiation
 ;;^UTILITY(U,$J,358.3,23060,2)
 ;;=^295285
 ;;^UTILITY(U,$J,358.3,23061,0)
 ;;=V10.61^^125^1400^37
 ;;^UTILITY(U,$J,358.3,23061,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23061,1,4,0)
 ;;=4^V10.61
 ;;^UTILITY(U,$J,358.3,23061,1,5,0)
 ;;=5^Hx of Lymphoid Leukemia
 ;;^UTILITY(U,$J,358.3,23061,2)
 ;;=Hx of Lymphoid Leukemia^295232
 ;;^UTILITY(U,$J,358.3,23062,0)
 ;;=V12.03^^125^1400^39
 ;;^UTILITY(U,$J,358.3,23062,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23062,1,4,0)
 ;;=4^V12.03
 ;;^UTILITY(U,$J,358.3,23062,1,5,0)
 ;;=5^Hx of Malaria
 ;;^UTILITY(U,$J,358.3,23062,2)
 ;;=Hx of Malaria^303395
 ;;^UTILITY(U,$J,358.3,23063,0)
 ;;=V10.82^^125^1400^40
 ;;^UTILITY(U,$J,358.3,23063,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23063,1,4,0)
 ;;=4^V10.82
 ;;^UTILITY(U,$J,358.3,23063,1,5,0)
 ;;=5^Hx of Malignant Melanoma
 ;;^UTILITY(U,$J,358.3,23063,2)
 ;;=Hx of Malignant Melanoma^295240
 ;;^UTILITY(U,$J,358.3,23064,0)
 ;;=V10.62^^125^1400^43
 ;;^UTILITY(U,$J,358.3,23064,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23064,1,4,0)
 ;;=4^V10.62
 ;;^UTILITY(U,$J,358.3,23064,1,5,0)
 ;;=5^Hx of Myeloid Leukemia
 ;;^UTILITY(U,$J,358.3,23064,2)
 ;;=Hx of Myeloid Leukemia^295233
 ;;^UTILITY(U,$J,358.3,23065,0)
 ;;=V10.63^^125^1400^41
 ;;^UTILITY(U,$J,358.3,23065,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23065,1,4,0)
 ;;=4^V10.63
 ;;^UTILITY(U,$J,358.3,23065,1,5,0)
 ;;=5^Hx of Monocytic Leukemia
 ;;^UTILITY(U,$J,358.3,23065,2)
 ;;=Hx of Monocytic Leukemia^295234
 ;;^UTILITY(U,$J,358.3,23066,0)
 ;;=V11.2^^125^1400^32
 ;;^UTILITY(U,$J,358.3,23066,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23066,1,4,0)
 ;;=4^V11.2
 ;;^UTILITY(U,$J,358.3,23066,1,5,0)
 ;;=5^Hx of Dysthymia
 ;;^UTILITY(U,$J,358.3,23066,2)
 ;;=Hx of Dysthymia^295251
 ;;^UTILITY(U,$J,358.3,23067,0)
 ;;=V15.81^^125^1400^60
 ;;^UTILITY(U,$J,358.3,23067,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23067,1,4,0)
 ;;=4^V15.81
 ;;^UTILITY(U,$J,358.3,23067,1,5,0)
 ;;=5^Noncompliance With Medical Treatment
 ;;^UTILITY(U,$J,358.3,23067,2)
 ;;=^295290
 ;;^UTILITY(U,$J,358.3,23068,0)
 ;;=V10.43^^125^1400^44
 ;;^UTILITY(U,$J,358.3,23068,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23068,1,4,0)
 ;;=4^V10.43
 ;;^UTILITY(U,$J,358.3,23068,1,5,0)
 ;;=5^Hx of Ovarian CA
 ;;
 ;;$END ROU IBDEI1AX
